Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Other Non-Current Assets: 2017-2024

Historic Other Non-Current Assets for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Dec 2024 value amounting to $2.8 million.

  • Crinetics Pharmaceuticals' Other Non-Current Assets rose 1317.85% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year increase of 1317.85%. This contributed to the annual value of $2.8 million for FY2024, which is 41.45% up from last year.
  • Crinetics Pharmaceuticals' Other Non-Current Assets amounted to $2.8 million in FY2024, which was up 41.45% from $2.0 million recorded in FY2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Other Non-Current Assets ranged from a high of $2.8 million in FY2024 and a low of $500,000 during FY2020.
  • Moreover, its 3-year median value for Other Non-Current Assets was $2.0 million (2023), whereas its average is $2.0 million.
  • Data for Crinetics Pharmaceuticals' Other Non-Current Assets shows a peak YoY skyrocketed of 160.20% (in 2022) over the last 5 years.
  • Crinetics Pharmaceuticals' Other Non-Current Assets (Yearly) stood at $500,000 in 2020, then remained steady at $500,000 in 2021, then spiked by 160.20% to $1.3 million in 2022, then soared by 53.73% to $2.0 million in 2023, then soared by 41.45% to $2.8 million in 2024.